Scilex Holding Company (SCLX) - Total Liabilities
Based on the latest financial reports, Scilex Holding Company (SCLX) has total liabilities worth $547.71 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Scilex Holding Company to track the company's year-over-year net asset growth rate.
Scilex Holding Company - Total Liabilities Trend (2020–2025)
This chart illustrates how Scilex Holding Company's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Scilex Holding Company to measure how efficiently the company converts operating cash flow to free cash.
Scilex Holding Company Competitors by Total Liabilities
The table below lists competitors of Scilex Holding Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ralco Agencies Ltd
TA:RLCO
|
Israel | ILA71.02 Million |
|
Regal Holding Co Ltd
TW:4807
|
Taiwan | NT$940.14 Million |
|
Talphera Inc.
NASDAQ:TLPH
|
USA | $12.68 Million |
|
Lion Chemtech Co. Ltd
KQ:171120
|
Korea | ₩26.84 Billion |
|
Caprice Resources Limited
F:C3F
|
Germany | €375.09K |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
Thailand | ฿390.27 Million |
|
Ozderici Gayrimenkul Yatirim Ortakligi AS
IS:OZGYO
|
Turkey | TL364.02 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Scilex Holding Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SCLX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scilex Holding Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scilex Holding Company (2020–2025)
The table below shows the annual total liabilities of Scilex Holding Company from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $576.73 Million | +101.94% |
| 2024-12-31 | $285.59 Million | +4.14% |
| 2023-12-31 | $274.25 Million | +445.35% |
| 2022-12-31 | $50.29 Million | -83.34% |
| 2021-12-31 | $301.81 Million | +35.23% |
| 2020-12-31 | $223.19 Million | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more